Wilms8 Cells

Categories: Kidney cancer cell lines Description: The Wilms8 cell line was derived from a primary Wilms tumor in a pediatric patient with a germline WT1 mutation. This cell line is characterized by a homozygous nonsense mutation in the WT1 gene (c.1168 C>T, p.R390X), leading to a complete loss of WT1 function. WT1 is crucial for normal kidney development, and its inactivation is a common feature in certain aggressive subtypes of Wilms tumor, particularly those that exhibit mesenchymal differentiation. Wilms8, therefore, provides a valuable model for studying the effects of WT1 loss on tumorigenesis, especially in the context of Wilms tumors that arise with a pronounced stromal component. In addition to the WT1 mutation, Wilms8 cells harbor a mutation in the CTNNB1 gene (p.S45A), which encodes beta-Catenin, a key regulator of the Wnt signaling pathway. The mutation at serine 45 disrupts the normal phosphorylation process that leads to beta-Catenin degradation, causing its stabilization and accumulation in the nucleus. This results in the constitutive activation of Wnt signaling, which drives cell proliferation and contributes to the oncogenic properties of the Wilms8 cell line. The interplay between WT1 loss and aberrant Wnt signaling in Wilms8 makes it a crucial model for understanding the molecular mechanisms underlying these pathways in Wilms tumor biology. Wilms8 cells display a mesenchymal phenotype, characterized by the expression of vimentin and the absence of epithelial markers such as cytokeratin. This aligns with the stromal differentiation observed in the original tumor. The cells demonstrate a limited ability to undergo further mesenchymal differentiation, such as forming muscle-like cells under specific conditions. Proteomic analyses of Wilms8 have revealed the activation of multiple receptor tyrosine kinases (RTKs), including PDGFRbeta and AXL, which are involved in key processes such as cell survival, migration, and proliferation. The activation of downstream signaling pathways, particularly the MAPK and PI3K/AKT pathways, further contributes to the aggressive characteristics of Wilms8 cells. Overall, the Wilms8 cell line serves as an essential tool for investigating the molecular basis of Wilms tumor driven by WT1 loss and aberrant Wnt signaling. Its genetic and phenotypic features make it a robust platform for studying the interaction between these critical pathways and for identifying potential therapeutic targets in Wilms tumors with a stromal component. Organism: Human Tissue: Kidney Disease: Wilms tumor Age: 8 months Gender: Male Ethnicity: Caucasian Morphology: Spindle-shaped Cell Type: Wilms cells Growth Properties: Adherent Citation: Wilms8 (Cytion catalog number 300416) Biosafety Level: 1 Ncbi_ Taxid: 9606.0 Cellosaurus Accession: CVCL_A5SJ Mutational Profile: WT1 mutation status: homozygous c.1168C>T, p.390x, LOH: , CTNNB1 mutation status: heterozygous TCT>GCT, p.S45A Culture Medium: MSCGM kit (from Lonza) Dissociation Reagent: Accutase Subculturing: Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. Freeze Medium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Thawing And Culturing Cells: Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks, for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes. Sterility: Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. Safety Precautions: When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments. Warranty: We stand by the promise of delivering products with high cell viability and robust culture performance. To achieve the best results, please make sure you follow the storage and culture instructions detailed in the product information sheet closely. Your adherence to these guidelines is key to success. Subject To Material Transfer Agreements: If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement. Required Product 3: 860015.0 Required Product 4: 830100.0